Fulcrum Capital’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.9M | Sell |
131,371
-5,965
| -4% | -$500K | 2.41% | 12 |
|
|
2026
Q1 | $11M | Buy |
137,336
+116
| +0.1% | +$9.56K | 2.39% | 15 |
|
|
2025
Q4 | $11.7M | Buy |
137,220
+3,352
| +3% | +$275K | 2.35% | 13 |
|
|
2025
Q3 | $10.4M | Buy |
133,868
+2,759
| +2% | +$216K | 2.13% | 16 |
|
|
2025
Q2 | $10.3M | Buy |
131,109
+4,842
| +4% | +$361K | 2.17% | 16 |
|
|
2025
Q1 | $9.15M | Buy |
126,267
+4,255
| +3% | +$305K | 2.03% | 17 |
|
|
2024
Q4 | $9.03M | Buy |
122,012
+4,107
| +3% | +$287K | 1.89% | 17 |
|
|
2024
Q3 | $7.78M | Buy |
117,905
+4,067
| +4% | +$295K | 1.69% | 23 |
|
|
2024
Q2 | $10.5M | Buy |
113,838
+267
| +0.2% | +$23.6K | 2.39% | 11 |
|
|
2024
Q1 | $10.9M | Buy |
113,571
+479
| +0.4% | +$40.2K | 2.58% | 11 |
|
|
2023
Q4 | $8.62M | Buy |
113,092
+19,096
| +20% | +$1.33M | 2.23% | 15 |
|
|
2023
Q3 | $6.51M | Buy |
93,996
+322
| +0.3% | +$25.9K | 1.89% | 18 |
|
|
2023
Q2 | $8.84M | Sell |
93,674
-3,069
| -3% | -$267K | 2.32% | 12 |
|
|
2023
Q1 | $8M | Buy |
96,743
+7,034
| +8% | +$553K | 2.15% | 14 |
|
|
2022
Q4 | $6.69M | Buy |
89,709
+6,439
| +8% | +$496K | 1.93% | 19 |
|
|
2022
Q3 | $6.88M | Sell |
83,270
-2,487
| -3% | -$239K | 2.04% | 19 |
|
|
2022
Q2 | $8.15M | Sell |
85,757
-1,212
| -1% | -$125K | 2.56% | 13 |
|
|
2022
Q1 | $10.2M | Buy |
86,969
+774
| +0.9% | +$86.8K | 2.74% | 11 |
|
|
2021
Q4 | $11.2M | Buy |
86,195
+1,039
| +1% | +$121K | 2.42% | 13 |
|
|
2021
Q3 | $9.64M | Buy |
85,156
+106
| +0.1% | +$12.1K | 2.31% | 11 |
|
|
2021
Q2 | $8.81M | Buy |
85,050
+2,300
| +3% | +$217K | 2.21% | 17 |
|
|
2021
Q1 | $6.92M | Buy |
82,750
+3,454
| +4% | +$292K | 1.98% | 22 |
|
|
2020
Q4 | $7.23M | Buy |
79,296
+3,749
| +5% | +$311K | 2.16% | 18 |
|
|
2020
Q3 | $6.03M | Sell |
75,547
-6,776
| -8% | -$529K | 2.18% | 25 |
|
|
2020
Q2 | $5.69M | Sell |
82,323
-4,461
| -5% | -$317K | 2.16% | 26 |
|
|
2020
Q1 | $5.46M | Buy |
86,784
+330
| +0.4% | +$23.8K | 2.48% | 23 |
|
|
2019
Q4 | $6.72M | Buy |
86,454
+222
| +0.3% | +$17.3K | 2.08% | 20 |
|
|
2019
Q3 | $6.32M | Sell |
86,232
-81
| -0.1% | -$5.69K | 2.16% | 17 |
|
|
2019
Q2 | $5.32M | Buy |
86,313
+18,786
| +28% | +$1.14M | 1.95% | 26 |
|
|
2019
Q1 | $4.31M | Buy |
67,527
+1,995
| +3% | +$114K | 1.63% | 31 |
|
|
2018
Q4 | $3.35M | Buy |
65,532
+3,930
| +6% | +$199K | 1.51% | 32 |
|
|
2018
Q3 | $3.58M | Buy |
61,602
+1,428
| +2% | +$69.8K | 1.39% | 31 |
|
|
2018
Q2 | $2.92M | Buy |
+60,174
| New | +$2.81M | 1.39% | 28 |
|
Other funds holding EW
Fulcrum Capital's EW Position: Q2 2026 in Review
Fulcrum Capital reduced its Edwards Lifesciences (EW) stake by 4.3% in Q2 2026, selling an estimated $500K and leaving 131,371 shares worth $11.9M. The position accounts for 2.41% of the portfolio, ranked #12.
Fulcrum Capital first reported a position in EW in Q2 2018 and has held it in 33 quarters since. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Fulcrum Capital held 131,371 shares of Edwards Lifesciences worth $11.9M as of Q2 2026.
- Fulcrum Capital sold 5,965 Edwards Lifesciences shares in Q2 2026, an estimated $500K.
- Edwards Lifesciences made up 2.41% of Fulcrum Capital's portfolio in Q2 2026, its #12 holding.
- Fulcrum Capital first reported a position in Edwards Lifesciences in Q2 2018 and has held it in 33 quarters since.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Fulcrum Capital's 13F filing for Q2 2026, filed 21 Jul 2026.